| Drug Name |
Irinotecan hydrochloride |
| Drug ID |
BADD_D01196 |
| Description |
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). |
| Indications and Usage |
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01CE02 |
| DrugBank ID |
DB00762
|
| KEGG ID |
D01061
|
| MeSH ID |
D000077146
|
| PubChem ID |
74990
|
| TTD Drug ID |
D07HOB
|
| NDC Product Code |
0143-9583; 72485-211; 67184-0511; 45963-614; 67184-0513; 55150-352; 0009-7529; 17337-0307; 65129-1025; 16714-027; 68083-382; 25021-230; 59923-714; 63323-193; 16714-131; 59923-702; 70700-170; 57884-0009; 72485-213; 61703-349; 59923-715; 59923-716; 55150-354; 50742-401; 72485-212; 50742-402; 61200-112; 0143-9701; 15054-0043; 14778-1111; 55150-353; 12780-4860; 60505-6128; 67184-0014; 0143-9702; 67184-0512 |
| Synonyms |
Irinotecan | Irrinotecan | Camptothecin-11 | Camptothecin 11 | SN 38 11 | SN-38-11 | SN3811 | SN 38 | SN-38 | NK012 Compound | CPT-11 | CPT11 | CPT 11 | Camptosar | 7-Ethyl-10-hydroxycamptothecin | 7 Ethyl 10 hydroxycamptothecin | Irinotecan Hydrochloride |
